Since the US Food and Drug Agency’s (FDA) 1998 approval of trastuzumab [4], additional HER2-directed therapies have been approved, and their use has dramatically improved progression-free and overall survival for patients with advanced HER2-positive breast cancer [5–9]. This evidence concerns the gene ERBB2 and breast carcinoma.